517 related articles for article (PubMed ID: 34514191)
1. Mineralocorticoid Receptor Antagonism in Chronic Kidney Disease.
Georgianos PI; Agarwal R
Kidney Int Rep; 2021 Sep; 6(9):2281-2291. PubMed ID: 34514191
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of nonsteroidal mineralocorticoid receptor antagonists in patients with diabetic kidney disease.
Lerma E; White WB; Bakris G
Postgrad Med; 2023 Apr; 135(3):224-233. PubMed ID: 35392754
[TBL] [Abstract][Full Text] [Related]
3. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine.
Agarwal R; Kolkhof P; Bakris G; Bauersachs J; Haller H; Wada T; Zannad F
Eur Heart J; 2021 Jan; 42(2):152-161. PubMed ID: 33099609
[TBL] [Abstract][Full Text] [Related]
4. Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes.
Lerma EV; Wilson DJ
Expert Rev Clin Pharmacol; 2022 May; 15(5):501-513. PubMed ID: 35762406
[TBL] [Abstract][Full Text] [Related]
5. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
Marzolla V; Infante M; Armani A; Rizzo M; Caprio M
Expert Opin Drug Saf; 2022 Sep; 21(9):1161-1170. PubMed ID: 36174659
[TBL] [Abstract][Full Text] [Related]
7. Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - New perspectives for combination therapy.
Kolkhof P; Joseph A; Kintscher U
Pharmacol Res; 2021 Oct; 172():105859. PubMed ID: 34461222
[TBL] [Abstract][Full Text] [Related]
8. The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature.
Georgianos PI; Agarwal R
Am J Hypertens; 2023 Feb; 36(3):135-143. PubMed ID: 36331811
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular-renal protective effect and molecular mechanism of finerenone in type 2 diabetic mellitus.
Lv R; Xu L; Che L; Liu S; Wang Y; Dong B
Front Endocrinol (Lausanne); 2023; 14():1125693. PubMed ID: 36860374
[TBL] [Abstract][Full Text] [Related]
10. Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus.
Wish JB; Pergola P
Mayo Clin Proc Innov Qual Outcomes; 2022 Dec; 6(6):536-551. PubMed ID: 36277502
[TBL] [Abstract][Full Text] [Related]
11. Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.
Pandey AK; Bhatt DL; Cosentino F; Marx N; Rotstein O; Pitt B; Pandey A; Butler J; Verma S
Eur Heart J; 2022 Aug; 43(31):2931-2945. PubMed ID: 35713973
[TBL] [Abstract][Full Text] [Related]
12. Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes.
Rossing P
Kidney Int Suppl (2011); 2022 Apr; 12(1):27-35. PubMed ID: 35529090
[TBL] [Abstract][Full Text] [Related]
13. Nonsteroidal Mineralocorticoid Receptor Antagonist (Finerenone) in Cardiorenal Disease.
Shah M; Awad AS; Abdel-Rahman EM
J Clin Med; 2023 Sep; 12(19):. PubMed ID: 37834929
[TBL] [Abstract][Full Text] [Related]
14. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity.
Grune J; Beyhoff N; Smeir E; Chudek R; Blumrich A; Ban Z; Brix S; Betz IR; Schupp M; Foryst-Ludwig A; Klopfleisch R; Stawowy P; Houtman R; Kolkhof P; Kintscher U
Hypertension; 2018 Apr; 71(4):599-608. PubMed ID: 29437893
[TBL] [Abstract][Full Text] [Related]
15. Cardiorenal Benefits of Finerenone in Different Races and Kidney Function in Patients with Chronic Kidney Disease.
Li P; Cui Y; Xu X; Dong J; Liao L
Cardiorenal Med; 2024; 14(1):227-234. PubMed ID: 38537621
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
Pitt B; Anker SD; Böhm M; Gheorghiade M; Køber L; Krum H; Maggioni AP; Ponikowski P; Voors AA; Zannad F; Nowack C; Kim SY; Pieper A; Kimmeskamp-Kirschbaum N; Filippatos G
Eur J Heart Fail; 2015 Feb; 17(2):224-32. PubMed ID: 25678098
[TBL] [Abstract][Full Text] [Related]
17. Aldosterone, Mineralocorticoid Receptor Activation, and CKD: A Review of Evolving Treatment Paradigms.
Epstein M; Kovesdy CP; Clase CM; Sood MM; Pecoits-Filho R
Am J Kidney Dis; 2022 Nov; 80(5):658-666. PubMed ID: 36057467
[TBL] [Abstract][Full Text] [Related]
18. [Finerenone cardiorenal effects and its placement in treatment of chronic kidney disease in patients with type 2 diabetes mellitus: A review].
Salukhov VV; Shamkhalova MS; Duganova AV
Ter Arkh; 2023 Apr; 95(3):261-273. PubMed ID: 37167149
[TBL] [Abstract][Full Text] [Related]
19. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
Kolkhof P; Delbeck M; Kretschmer A; Steinke W; Hartmann E; Bärfacker L; Eitner F; Albrecht-Küpper B; Schäfer S
J Cardiovasc Pharmacol; 2014 Jul; 64(1):69-78. PubMed ID: 24621652
[TBL] [Abstract][Full Text] [Related]
20. Finerenone : third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease.
Liu LC; Schutte E; Gansevoort RT; van der Meer P; Voors AA
Expert Opin Investig Drugs; 2015; 24(8):1123-35. PubMed ID: 26095025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
